Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: Results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up

Lihteh Wu, J Fernando Arevalo, Mauricio Maia, Maria H. Berrocal, Juan Sanchez, Teodoro Evans

Research output: Contribution to journalArticle

Abstract

Purpose: To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months. Methods: This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg). Results: The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained ≥3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost ≥3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by ≥3 lines, and four (16%) lost ≥3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 ± 201 μm at baseline to 268 ± 96 μm, compared with a decrease from 388 ± 162 to 296 ± 114 μm in the 2.5-mg group (P = 0.7896). Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.

Original languageEnglish (US)
Pages (from-to)125-130
Number of pages6
JournalJapanese Journal of Ophthalmology
Volume53
Issue number2
DOIs
StatePublished - Mar 2009

Fingerprint

Choroidal Neovascularization
Macular Degeneration
Retina
Visual Acuity
Diabetic Retinopathy
Injections
Multicenter Studies
Bevacizumab
Therapeutics

Keywords

  • Age-related macular degeneration
  • Bevacizumab
  • Choroidal neovascularization
  • VEGF

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{d076033911904ea6b278f0cdb50893fc,
title = "Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: Results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up",
abstract = "Purpose: To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months. Methods: This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg). Results: The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46{\%}) eyes gained ≥3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20{\%}) lost ≥3 lines of ETDRS VA. In the 2.5-mg group, 11 (44{\%}) eyes improved by ≥3 lines, and four (16{\%}) lost ≥3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 ± 201 μm at baseline to 268 ± 96 μm, compared with a decrease from 388 ± 162 to 296 ± 114 μm in the 2.5-mg group (P = 0.7896). Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.",
keywords = "Age-related macular degeneration, Bevacizumab, Choroidal neovascularization, VEGF",
author = "Lihteh Wu and Arevalo, {J Fernando} and Mauricio Maia and Berrocal, {Maria H.} and Juan Sanchez and Teodoro Evans",
year = "2009",
month = "3",
doi = "10.1007/s10384-008-0622-y",
language = "English (US)",
volume = "53",
pages = "125--130",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab

T2 - Results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up

AU - Wu, Lihteh

AU - Arevalo, J Fernando

AU - Maia, Mauricio

AU - Berrocal, Maria H.

AU - Sanchez, Juan

AU - Evans, Teodoro

PY - 2009/3

Y1 - 2009/3

N2 - Purpose: To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months. Methods: This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg). Results: The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained ≥3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost ≥3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by ≥3 lines, and four (16%) lost ≥3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 ± 201 μm at baseline to 268 ± 96 μm, compared with a decrease from 388 ± 162 to 296 ± 114 μm in the 2.5-mg group (P = 0.7896). Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.

AB - Purpose: To compare the total number of injections and the anatomic and best-corrected visual acuity (VA) response after injecting 1.25 or 2.5 mg of bevacizumab as needed in patients with primary choroidal neovascularization secondary to age-related macular degeneration (AMD) at 12 months. Methods: This was a retrospective, interventional, comparative multicenter study of 60 eyes treated with intravitreal bevacizumab (35 eyes, 1.25 mg; 25 eyes, 2.5 mg). Results: The mean number of injections per eye was 3.8 in the 1.25-mg group and 3.2 in the 2.5-mg group (P = 0.2752). At 12 months, in the 1.25-mg group, 16 (46%) eyes gained ≥3 lines of Early Treatment Diabetic Retinopathy Study (ETDRS) VA and seven (20%) lost ≥3 lines of ETDRS VA. In the 2.5-mg group, 11 (44%) eyes improved by ≥3 lines, and four (16%) lost ≥3 lines (P = 1.000). At 12 months, in the 1.25-mg group, the mean central macular thickness decreased from 419 ± 201 μm at baseline to 268 ± 96 μm, compared with a decrease from 388 ± 162 to 296 ± 114 μm in the 2.5-mg group (P = 0.7896). Conclusion: There were no statistically significant differences between the two dose groups with regard to the number of injections, anatomic and VA outcomes.

KW - Age-related macular degeneration

KW - Bevacizumab

KW - Choroidal neovascularization

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=63849316464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849316464&partnerID=8YFLogxK

U2 - 10.1007/s10384-008-0622-y

DO - 10.1007/s10384-008-0622-y

M3 - Article

C2 - 19333696

AN - SCOPUS:63849316464

VL - 53

SP - 125

EP - 130

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 2

ER -